Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Drop in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 415,300 shares, a drop of 20.6% from the August 31st total of 523,200 shares. Currently, 9.1% of the company’s stock are short sold. Based on an average daily volume of 5,830,000 shares, the days-to-cover ratio is presently 0.1 days.

Virpax Pharmaceuticals Price Performance

Shares of NASDAQ VRPX opened at $0.68 on Friday. Virpax Pharmaceuticals has a fifty-two week low of $0.46 and a fifty-two week high of $9.00. The firm’s 50-day simple moving average is $0.95 and its 200 day simple moving average is $1.68.

Virpax Pharmaceuticals (NASDAQ:VRPX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($1.75) EPS for the quarter.

Analyst Ratings Changes

Separately, Maxim Group upgraded shares of Virpax Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Friday, July 19th.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.